Spots Global Cancer Trial Database for Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
Official Title: A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma
Study ID: NCT00596804
Interventions
Study Description
Brief Summary: This study is being done to assess the safety and tolerance of different doses of humanized hA20 in patients with NHL.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Service Des Maladies Du Sang, Lille, Cedex, France
Centre hospitalier Lyon, Lyon, Pierre Benite Cedex, France
University of Leicester, Leicester, , United Kingdom
Contact Details
Name: William Wegener, MD, PhD
Affiliation: Gilead Sciences
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
